Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chemomab Therapeutics Ltd ADR (NQ: CMMB )

0.8324 -0.0076 (-0.90%)
Streaming Delayed Price Updated: 12:39 PM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 45,494
Open 0.8500
Bid (Size) 0.8200 (6)
Ask (Size) 0.8800 (20)
Prev. Close 0.8400
Today's Range 0.8200 - 0.8800
52wk Range 0.4200 - 1.790
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
From Chemomab Therapeutics
Via GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024
Chemomab Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+54.78%
+54.78%
1 Month
+26.14%
+26.14%
3 Month
+23.14%
+23.14%
6 Month
+49.98%
+49.98%
1 Year
-52.43%
-52.43%

More News

Read More
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
From Chemomab Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Earnings Scheduled For March 7, 2024
Via Benzinga
Why M.D.C. Holdings Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Children's Place Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Palo Alto Networks Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Crude Oil Falls 2%; TJX Issues Weak Earnings Outlook
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
US Stocks Gain; Producer Prices Fall In October
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.